NZ562772A - Tricyclic spiro derivatives as CRTH2 modulators - Google Patents

Tricyclic spiro derivatives as CRTH2 modulators

Info

Publication number
NZ562772A
NZ562772A NZ562772A NZ56277206A NZ562772A NZ 562772 A NZ562772 A NZ 562772A NZ 562772 A NZ562772 A NZ 562772A NZ 56277206 A NZ56277206 A NZ 56277206A NZ 562772 A NZ562772 A NZ 562772A
Authority
NZ
New Zealand
Prior art keywords
chloro
pyrrolidin
indole
trioxospiro
acetic acid
Prior art date
Application number
NZ562772A
Other languages
English (en)
Inventor
Matthias Schwarz
Eric Sebille
Christophe Cleva
Cedric Merlot
Dennis Chruch
Patrick Page
Jacqueline A Macritchie
John Frederick Atherall
Stefano Crosignani
Doris Pupowicz
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NZ562772A publication Critical patent/NZ562772A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ562772A 2005-05-24 2006-05-23 Tricyclic spiro derivatives as CRTH2 modulators NZ562772A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05104428 2005-05-24
US68863105P 2005-06-08 2005-06-08
PCT/EP2006/062545 WO2006125784A1 (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as crth2 modulators

Publications (1)

Publication Number Publication Date
NZ562772A true NZ562772A (en) 2010-01-29

Family

ID=35478408

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ562772A NZ562772A (en) 2005-05-24 2006-05-23 Tricyclic spiro derivatives as CRTH2 modulators

Country Status (20)

Country Link
US (1) US8236963B2 (enExample)
EP (1) EP1891075B1 (enExample)
JP (1) JP5567268B2 (enExample)
KR (1) KR101333861B1 (enExample)
CN (1) CN101300259B (enExample)
AR (1) AR055959A1 (enExample)
AT (1) ATE529429T1 (enExample)
AU (1) AU2006251138C1 (enExample)
BR (1) BRPI0610209A2 (enExample)
CA (1) CA2602965C (enExample)
DK (1) DK1891075T3 (enExample)
ES (1) ES2375614T3 (enExample)
MX (1) MX2007014256A (enExample)
NZ (1) NZ562772A (enExample)
PL (1) PL1891075T3 (enExample)
PT (1) PT1891075E (enExample)
RU (1) RU2478639C2 (enExample)
UA (1) UA90145C2 (enExample)
WO (1) WO2006125784A1 (enExample)
ZA (1) ZA200709819B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101500996B (zh) 2006-08-07 2012-07-04 埃科特莱茵药品有限公司 (3-胺基-1,2,3,4-四氢-9h-咔唑-9-基)-乙酸衍生物
CA2766883A1 (en) 2009-07-15 2011-01-20 Merck Serono S.A. Tricyclic indole-derived spiro derivatives as crth2 modulators
UA107814C2 (uk) 2009-11-12 2015-02-25 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Спірооксіндольні антагоністи мdм2
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
TWI535723B (zh) 2010-11-12 2016-06-01 密西根大學董事會 螺-吲哚酮mdm2拮抗劑
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
JP2014513699A (ja) 2011-05-11 2014-06-05 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン スピロ−オキシインドールmdm2アンタゴニスト
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
CN103554118B (zh) * 2013-10-15 2015-08-19 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物及其应用
CN103554119B (zh) * 2013-10-15 2015-09-16 华东师范大学 四氢呋喃并苯并二氢吡喃多环化合物的制备方法
CN103554120B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物的制备方法
CN103554121B (zh) * 2013-10-16 2015-06-24 华东师范大学 3,3-螺(2-四氢呋喃)氧化吲哚多环状化合物及其应用
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
RU2016140708A (ru) 2014-03-18 2018-04-18 Идорсиа Фармасьютиклз Лтд Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
KR20170124602A (ko) 2015-03-13 2017-11-10 포르마 세라퓨틱스 인크. Hdac8 억제제로서의 알파-신나미드 화합물 및 조성물
MA42442B1 (fr) 2015-07-15 2019-07-31 Hoffmann La Roche Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
RU2631856C1 (ru) * 2016-05-04 2017-09-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" Способ получения аммонийных солей 3-амино-8-гидрокси-1,6-диоксо-4-циано-2,7-диазаспиро[4.4]нон-3-ен-2-идов
MA45665B1 (fr) 2016-07-18 2020-11-30 Hoffmann La Roche Dérivés d'éthynyle
CN109384787B (zh) * 2017-08-08 2021-04-16 沈阳药科大学 一种一价银催化的氢化吡啶螺二氢吲哚环的合成方法
CN109369658B (zh) * 2017-08-08 2020-01-31 沈阳药科大学 一种螺[吡咯烷-3,3`-氧化吲哚]环系的合成方法
CN109384794B (zh) * 2017-08-08 2020-06-19 沈阳药科大学 质子酸催化的一类四环吲哚骨架的合成方法
KR101857408B1 (ko) * 2018-02-28 2018-05-14 경북대학교 산학협력단 탈모 예방 또는 치료용 조성물
EP3902805A4 (en) 2018-12-28 2023-03-01 SPV Therapeutics Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
CN112876488B (zh) * 2021-02-18 2021-12-21 苏州大学 螺环吲哚啉衍生物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE53102B1 (en) 1981-05-12 1988-06-22 Ici Plc Pharmaceutical spiro-succinimide derivatives
IE52879B1 (en) * 1981-05-12 1988-03-30 Ici Plc Pharmaceutical spiro-hydantoin derivatives
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
IL144897A0 (en) * 1999-03-12 2002-06-30 Boehringer Ingelheim Pharma Compounds useful as anti-inflammatory agents
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
GB2388540A (en) * 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
EA011385B1 (ru) 2002-10-04 2009-02-27 Миллениум Фармасьютикалз, Инк. Антагонисты рецептора pgd2 для лечения воспалительных заболеваний
WO2004035543A1 (en) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Tetrahydroquinoline derivatives as crth2 antagonists
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
US20050038070A1 (en) 2003-07-09 2005-02-17 Amgen Inc. Asthma and allergic inflammation modulators
WO2005102338A1 (en) 2004-04-20 2005-11-03 Pfizer Limited Method of treating neuropathic pain using a crth2 receptor antagonist

Also Published As

Publication number Publication date
AR055959A1 (es) 2007-09-12
RU2007147430A (ru) 2009-06-27
AU2006251138A1 (en) 2006-11-30
DK1891075T3 (da) 2011-12-19
EP1891075B1 (en) 2011-10-19
JP2008542238A (ja) 2008-11-27
US20090318486A1 (en) 2009-12-24
KR20080031191A (ko) 2008-04-08
RU2478639C2 (ru) 2013-04-10
KR101333861B1 (ko) 2013-11-28
EP1891075A1 (en) 2008-02-27
US8236963B2 (en) 2012-08-07
AU2006251138B2 (en) 2012-08-09
CA2602965C (en) 2013-12-31
CN101300259B (zh) 2013-08-28
UA90145C2 (ru) 2010-04-12
BRPI0610209A2 (pt) 2010-06-01
MX2007014256A (es) 2008-03-26
WO2006125784A1 (en) 2006-11-30
CA2602965A1 (en) 2006-11-30
PL1891075T3 (pl) 2011-12-30
JP5567268B2 (ja) 2014-08-06
CN101300259A (zh) 2008-11-05
ES2375614T3 (es) 2012-03-02
PT1891075E (pt) 2011-11-10
ATE529429T1 (de) 2011-11-15
AU2006251138C1 (en) 2013-08-29
ZA200709819B (en) 2009-09-30

Similar Documents

Publication Publication Date Title
EP1891075B1 (en) Tricyclic spiro derivatives as crth2 modulators
CA2691776C (en) Substituted imidazoheterocycles
JP6116245B2 (ja) 神経変性疾患治療における使用のためのインドールアミン誘導体および関連化合物
JP5580330B2 (ja) Vegf−r2のピリジルオキシインドール類阻害剤および疾患の処置のためのその使用
RS52175B (sr) Hidroksimetil pirolidini kao agonisti beta 3 adrenergičkog receptora
JP2024522827A (ja) Cbl-b調節因子及びその使用
TW202019408A (zh) 稠合三環雜環化合物及其治療用途
KR20110106450A (ko) 바이시클릭 피라졸로-헤테로사이클
JP2024514847A (ja) Cbl-b修飾因子及びその使用
US8835422B2 (en) Substituted imidazoheterocycle derivatives
US8859538B2 (en) Uses of substituted imidazoheterocycles
JP2022521895A (ja) ファルネソイドx受容体モジュレータとしての置換二環式化合物
CN119855589A (zh) 杂环pad4抑制剂
HK1121146A1 (en) Tricyclic spiro derivatives as crth2 modulators
HK1121146B (en) Tricyclic spiro derivatives as crth2 modulators

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 23 MAY 2016 BY CPA GLOBAL

Effective date: 20130412

LAPS Patent lapsed